[HTML][HTML] First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
A Falco, M Leiva, A Blanco, G Cefarelli… - World Journal of …, 2022 - ncbi.nlm.nih.gov
BACKGROUND The targeted therapy cetuximab [directed at the epidermal growth factor
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …
First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study.
A Falco, M Leiva, A Blanco, G Cefarelli… - World Journal of …, 2022 - europepmc.org
Background The targeted therapy cetuximab [directed at the epidermal growth factor
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …
First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
A Falco, M Leiva, A Blanco… - World journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The targeted therapy cetuximab [directed at the epidermal growth factor
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …
First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study.
A Falco, M Leiva, A Blanco, G Cefarelli… - World Journal of …, 2022 - europepmc.org
Background The targeted therapy cetuximab [directed at the epidermal growth factor
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …